Q3 EPS Forecast for Abbott Laboratories Raised by Analyst

Abbott Laboratories (NYSE:ABT) – Equities research analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for Abbott Laboratories in a note issued to investors on Thursday, October 17th. William Blair analyst M. Kaczor now anticipates that the healthcare product maker will post earnings of $1.32 per share for the quarter, up from their previous forecast of $1.31. The consensus estimate for Abbott Laboratories’ current full-year earnings is $4.66 per share.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Wednesday, October 16th. The healthcare product maker reported $1.21 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.20 by $0.01. Abbott Laboratories had a return on equity of 20.18% and a net margin of 13.65%. The business had revenue of $10.64 billion during the quarter, compared to the consensus estimate of $10.55 billion. During the same period in the previous year, the company posted $1.14 EPS. The business’s quarterly revenue was up 4.9% compared to the same quarter last year.

A number of other equities analysts have also recently commented on ABT. Morgan Stanley raised their target price on Abbott Laboratories from $107.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 17th. Piper Sandler boosted their price objective on Abbott Laboratories from $131.00 to $133.00 and gave the company an “overweight” rating in a research note on Thursday, October 17th. Evercore ISI raised their target price on shares of Abbott Laboratories from $120.00 to $124.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Citigroup upped their price target on shares of Abbott Laboratories from $119.00 to $127.00 and gave the stock a “buy” rating in a research report on Thursday, August 22nd. Finally, Jefferies Financial Group raised their price objective on shares of Abbott Laboratories from $120.00 to $125.00 and gave the company a “hold” rating in a research report on Thursday, October 17th. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average price target of $129.67.

Abbott Laboratories Stock Down 2.0 %

ABT opened at $116.99 on Monday. The firm’s 50 day simple moving average is $114.16 and its two-hundred day simple moving average is $108.52. The company has a market capitalization of $203.52 billion, a PE ratio of 36.45, a PEG ratio of 2.74 and a beta of 0.72. Abbott Laboratories has a 1-year low of $91.64 and a 1-year high of $121.64. The company has a current ratio of 1.68, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Unique Wealth Strategies LLC purchased a new position in shares of Abbott Laboratories in the 2nd quarter worth approximately $28,000. Redmont Wealth Advisors LLC bought a new position in Abbott Laboratories during the first quarter valued at $30,000. Future Financial Wealth Managment LLC purchased a new stake in shares of Abbott Laboratories in the third quarter valued at $31,000. Itau Unibanco Holding S.A. bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth about $32,000. Finally, Ridgewood Investments LLC purchased a new position in shares of Abbott Laboratories during the 2nd quarter worth about $37,000. Institutional investors own 75.18% of the company’s stock.

Insider Buying and Selling at Abbott Laboratories

In other news, CEO Robert B. Ford sold 141,679 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $116.41, for a total transaction of $16,492,852.39. Following the sale, the chief executive officer now directly owns 220,059 shares of the company’s stock, valued at $25,617,068.19. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.10% of the stock is currently owned by company insiders.

Abbott Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, November 15th. Investors of record on Tuesday, October 15th will be paid a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Tuesday, October 15th. Abbott Laboratories’s payout ratio is presently 68.54%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.